Latest / Durham News Today | 2 Min News | The Daily News Now!
Gilead Wins Legal Battle on Biktarvy Pricing | Durham News
Gilead Sciences just won a major legal battle that could reshape U.S. drug pricing, as a federal appeals court blocked the import of cheaper foreign versions of its top HIV drug Biktarvy — a move that protects Gilead’s dominant revenue stream and forces insurers to pay full price. The court ruled the imported drugs weren’t equivalent due to different quality controls, siding with Gilead on trademark and unfair competition claims. This decision bolsters Gilead’s financial outlook, with HIV sales hitting $5.7 billion in Q2 and a raised full-year forecast, while also clearing up another legal…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.